title: Influence of adalimumab treatment on anastomotic strength, degree of inflammation, and collagen formation:  an experimental study on the small intestine of rabbits.
abstract: BACKGROUND
  Adalimumab is a TNF-α inhibitor, which has gained wide use in the treatment of inflammatory bowel diseases. The potential detrimental effect of TNF-α inhibitors on postoperative complications such as anastomotic leakage is unknown. The aim of this study was to investigate the effect of a single therapeutic dose of adalimumab on anastomotic strength inflammation and collagen formation.
  
  
  METHODS
  Twenty-eight female rabbits (1.8-2.2 kg) were allocated to subcutaneous injection with either adalimumab (1.5 mg/kg) (n=14) or placebo (n=14). One week after medication two separate end-to-end anastomoses were performed in the jejunum. The rabbits were killed on the third postoperative day. The anastomosis were subjected to tensile strength analysis and histopathological examination.
  
  
  RESULTS
  No statistically significant differences were found between the two groups regarding maximum tensile strength, inflammation parameters and collagen formation in the anastomosis area. Multiple regression analysis showed no association between maximum tensile strength histological changes, time under anaesthesia, duration of surgery, weight gain, weight loss and number of sutures in either group.
  
  
  CONCLUSIONS
  We found no statistically significant effect of a single therapeutic dose of adalimumab on anastomotic strength, histological parameters or collagen formation in rabbits.
authors: Department of Clinical Pathology, Odense University Hospital, Odense, Denmark.
authors: Thomas
authors: T
authors: Ploug
authors: Kristian
authors: K
authors: Andersen
authors: Katrine
authors: K
authors: Hansen
authors: Jacob
authors: J
authors: Hjelmborg
authors: Niels
authors: N
authors: Qvist
mesh_terms: D000068879:Adalimumab; D000714:Anastomosis, Surgical; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000494:pharmacology*; D015415:Biomarkers / Q000378:metabolism; D003094:Collagen / Q000378:metabolism; D004334:Drug Administration Schedule; D004751:Enteritis / Q000209:etiology; D005260:Female; D007279:Injections, Subcutaneous; D007583:Jejunum / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D016014:Linear Models; D011183:Postoperative Complications; D011817:Rabbits; D011897:Random Allocation; D016037:Single-Blind Method; D013718:Tensile Strength / Q000187:drug effects; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D003094:Collagen; D000068879:Adalimumab